AU2022360968A1 - Cyclopentylpyrazole cdk2 inhibitors - Google Patents

Cyclopentylpyrazole cdk2 inhibitors Download PDF

Info

Publication number
AU2022360968A1
AU2022360968A1 AU2022360968A AU2022360968A AU2022360968A1 AU 2022360968 A1 AU2022360968 A1 AU 2022360968A1 AU 2022360968 A AU2022360968 A AU 2022360968A AU 2022360968 A AU2022360968 A AU 2022360968A AU 2022360968 A1 AU2022360968 A1 AU 2022360968A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
ring
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022360968A
Other languages
English (en)
Inventor
Melissa A. ASHLEY
Jessica Marie GRANDNER
Kevin M. Johnson
Steven Magnuson
Jeremy Mark MURRAY
Brendan T. PARR
Vishal A. Verma
Yong Wang
Mingshuo ZENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2022360968A1 publication Critical patent/AU2022360968A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022360968A 2021-10-05 2022-10-04 Cyclopentylpyrazole cdk2 inhibitors Pending AU2022360968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252394P 2021-10-05 2021-10-05
US63/252,394 2021-10-05
PCT/US2022/077501 WO2023060057A1 (en) 2021-10-05 2022-10-04 Cyclopentylpyrazole cdk2 inhibitors

Publications (1)

Publication Number Publication Date
AU2022360968A1 true AU2022360968A1 (en) 2024-02-29

Family

ID=84245758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022360968A Pending AU2022360968A1 (en) 2021-10-05 2022-10-04 Cyclopentylpyrazole cdk2 inhibitors

Country Status (10)

Country Link
US (1) US20240425478A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412995A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538694A (cg-RX-API-DMAC7.html)
KR (1) KR20240077491A (cg-RX-API-DMAC7.html)
CN (1) CN118019734A (cg-RX-API-DMAC7.html)
AR (1) AR127247A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022360968A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229067A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330501A (cg-RX-API-DMAC7.html)
WO (1) WO2023060057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
CA3250419A1 (en) * 2022-04-28 2025-07-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CYCLOPENTANOL ESTER DERIVATIVE SUBSTITUTED BY PYRAZOLE AND ITS USE
WO2024104455A1 (zh) * 2022-11-17 2024-05-23 山东绿叶制药有限公司 Cdk2抑制剂及其制备方法和应用
WO2025136671A1 (en) * 2023-12-20 2025-06-26 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128155C (en) * 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
CN113766125B (zh) 2019-09-29 2022-10-25 Oppo广东移动通信有限公司 对焦方法和装置、电子设备、计算机可读存储介质
MX2023009086A (es) * 2021-02-12 2023-08-08 Relay Therapeutics Inc Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos.

Also Published As

Publication number Publication date
KR20240077491A (ko) 2024-05-31
EP4412995A1 (en) 2024-08-14
AR127247A1 (es) 2024-01-03
WO2023060057A1 (en) 2023-04-13
CN118019734A (zh) 2024-05-10
CA3229067A1 (en) 2023-04-13
JP2024538694A (ja) 2024-10-23
US20240425478A1 (en) 2024-12-26
TW202330501A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
EP4412995A1 (en) Cyclopentylpyrazole cdk2 inhibitors
CA3221390A1 (en) Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266167A1 (en) Amide and urea-containing tricyclic kras inhibitors
RU2693480C2 (ru) Ингибиторы jak2 и alk2 и способы их использования
WO2022265974A1 (en) Aminoheterocycle-substituted tricyclic kras inhibitors
KR102589213B1 (ko) 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제
EA007063B1 (ru) ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β;
EP3555074B1 (en) Aminopyrazoles as selective janus kinase inhibitors
EP4034535B1 (en) Aza-quinoline compounds and uses thereof
JP6545262B2 (ja) Ripk2阻害剤およびそれを用いた癌の治療方法
JP2020526557A (ja) ムスカリン性アセチルコリン受容体m4のアンタゴニスト
JP2021512959A (ja) ピラゾロ[1,5−a][1,3,5]トリアジン−2−アミン誘導体、その製造法、およびその医薬用途
WO2019057112A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
TWI875911B (zh) Bruton酪胺酸激酶(BTK)抑制劑
EP3663285A1 (en) Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof
US10766883B2 (en) Aminopyrazoles as janus kinase inhibitors
CN107428762A (zh) 酞嗪酮衍生物、其制备方法及用途
TW201536783A (zh) 用於治療增生性失調之新穎化合物及其醫藥組合物
CN108299436B (zh) 黄嘌呤类化合物及其药物组合物和应用
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
CN118139846A (zh) 一种egfr小分子抑制剂、含其的药物组合物及其用途
JP2019518032A (ja) Pi3k beta阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
HK40110722A (en) Cyclopentylpyrazole cdk2 inhibitors
RU2830171C1 (ru) Ингибиторы BTK
WO2025034912A9 (en) Compounds for fgfr inhibition